首页> 美国卫生研究院文献>Cancers >Targeting PDK1 for Chemosensitization of Cancer Cells
【2h】

Targeting PDK1 for Chemosensitization of Cancer Cells

机译:靶向PDK1用于癌细胞的化学增敏

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite the rapid development in the field of oncology, cancer remains the second cause of mortality worldwide, with the number of new cases expected to more than double in the coming years. Chemotherapy is widely used to decelerate or stop tumour development in combination with surgery or radiation therapy when appropriate, and in many cases this improves the symptomatology of the disease. Unfortunately though, chemotherapy is not applicable to all patients and even when it is, there are many cases where a successful initial treatment period is followed by chemotherapeutic drug resistance. This is caused by a number of reasons, ranging from the genetic background of the patient (innate resistance) to the formation of tumour-initiating cells (acquired resistance). In this review, we discuss the potential role of PDK1 in the development of chemoresistance in different types of malignancy, and the design and application of potent inhibitors which can promote chemosensitization.
机译:尽管肿瘤学领域迅速发展,但是癌症仍然是全球范围内第二大死亡原因,在未来几年中,新病例的数量预计将增加一倍以上。在适当的情况下,化学疗法与外科手术或放射疗法相结合被广泛用于减缓或阻止肿瘤的发展,在许多情况下,这可改善疾病的症状。尽管不幸的是,化学疗法并不适用于所有患者,即使在许多情况下,成功的初始治疗期后都伴随着化学治疗药物耐药。这是由多种原因引起的,从患者的遗传背景(先天性抵抗力)到肿瘤引发细胞的形成(获得性抵抗力)不等。在这篇综述中,我们讨论了PDK1在不同类型恶性肿瘤化学耐药性发展中的潜在作用,以及可促进化学致敏作用的有效抑制剂的设计和应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号